NCT03296371Active, not recruiting
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
Genetics of Embryonal and Alveolar Rhabdomyosarcoma Study (GEARS)
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 19 Sept 2017
- Start date
- 23 Oct 2017
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Children's Oncology Group
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT03296371
What you commit to
- Study type: Observational
- Planned participants: 900
- From 23 Oct 2017 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- The patient must be enrolled on ACCRN07 and/or APEC14B1 and registered with COG by a North American member institution
- The patient must have a diagnosis of embryonal rhabdomyosarcoma or alveolar rhabdomyosarcoma
- The patient must be diagnosed with rhabdomyosarcoma between January 1, 2012 and November 30, 2019
- Concomitant treatment on a therapeutic trial is not required
- The patient must have at least one biological parent alive and willing to participate
- All questionnaire respondents must understand English or Spanish
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Age in the registry: - to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Childrens Oncology Group Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.